NCT04710576 2026-03-16AGAVE-201Syndax PharmaceuticalsPhase 2 Active not recruiting241 enrolled 11 charts 1 FDA
NCT04301778 2026-03-13Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic CholangiocarcinomaSidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2 Completed5 enrolled 13 charts
NCT07349771 2026-01-20Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS TrialMayo ClinicPhase 2 Not yet recruiting72 enrolled
NCT05491226 2025-08-27Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and RadiationCedars-Sinai Medical CenterPhase 2 Active not recruiting35 enrolled